Jesse I. Treu
Founding Partner @ Domain Associates
New York, United States
Jesse I. Treu is a Series B investor at Domain Associates in New York focused on Biotechnology and Health Care. Jesse I. Treu is the Board Member at Veracyte Inc.Dr. Treu has been a Partner of Domain since its inception in 1985. He has been a director of more than 30 early-stage healthcare companies, 18 of which have so far become successful public companies. At present, his board memberships include Afferent Pharmaceuticals, CoLucidPharmaceuticals, Regado Biosciences, Tandem Diabetes Care and Veracyte. He has served as a Founder, President and Chairman of numerous venture stage companies. Prior to the formation of Domain, Dr. Treu was vice president of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures. While at CW Ventures, he served as President and CEO of Microsonics, a pioneer in computer image processing for cardiology. Prior to that, Dr. Treu held executive positions at Technicon Instruments Corporation (now Siemens Medical Solutions Diagnostics), and at GE.Education:B.S. - Rensselaer Polytechnic Institute, 1968M.A. & Ph.D. - Princeton University, 1971, 1973
- Total investments:
- 13
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries Jesse I. Treu invests in
Stages Jesse I. Treu invests in
Countries Jesse I. Treu invests in
Investment Focus
Industry
- Biotechnology 5 (38%)
- Health Care 2 (15%)
- Medical Device 2 (15%)
- Pharmaceutical 2 (15%)
- Health Diagnostics 2 (15%)
Stage
- Series B 4 (31%)
- Series A 2 (15%)
- Series C 2 (15%)
- Funding Round 2 (15%)
- Series D 1 (8%)
Country
- United States 4 (31%)
- Canada 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Xagenic
|
Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation.This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples.We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results. | $10.8M / Series B / Jul 09, 2015 | |
CoLucid Pharmaceuticals
|
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders,chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina. | $37.1M / Series C / Jan 13, 2015 | |
Veracyte
|
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoidrisky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis are available to patients, and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. | $28M / Series C / Jun 28, 2013 | |
Afferent Pharmaceuticals
|
Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California. | $5M / Series B / Apr 01, 2013 | |
Regado Biosciences
|
Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronaryintervention. It was founded in 2001 and headquartered in Durham, North Carolina. | $51M / Series E / Dec 17, 2012 | |
|
Veracyte
|
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoidrisky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis are available to patients, and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. | $15M / Private Equity / Oct 01, 2012 | |
|
Veracyte
|
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoidrisky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis are available to patients, and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. | $15M / Oct 01, 2012 | |
|
CoLucid Pharmaceuticals
|
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders,chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina. | $7.5M / Aug 30, 2011 | |
|
Veracyte
|
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoidrisky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis are available to patients, and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. | $28M / Series B / Jun 11, 2010 | |
|
Regado Biosciences
|
Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronaryintervention. It was founded in 2001 and headquartered in Durham, North Carolina. | $40M / Series D / Dec 17, 2009 | |
| See all 13 investments → | |||
Co-Investors
Kleiner Perkins
4 deals together
Pappas Ventures
4 deals together
Pearl Street Venture Funds
4 deals together
Triathlon Medical Venture Partners
4 deals together
The Aurora Funds
2 deals together
Third Rock Ventures
2 deals together
About Domain Associates
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices,while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
Domain Associates Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brian Dovey
Partner
|
|||
Brian Halak
Partner
|
|||
Dennis Podlesak
Venture Capitalist
|
|||
Eckard Weber
Partner
|
|||
|
Jesse I. Treu
Founding Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jesse I. Treu invest in?
Jesse I. Treu invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series B and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Jesse I. Treu last invest?
The most recent investment recorded for Jesse I. Treu closed in Jul 2015. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
